Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. (NASDAQ: GALT) generates frequent news as a clinical-stage biopharmaceutical company developing galectin-targeted therapies for chronic liver disease and cancer. Most company updates focus on belapectin, its carbohydrate-based galectin-3 inhibitor, and the lead program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension.
On this page, readers can follow news about clinical data from the NAVIGATE trial and related analyses, including outcomes on liver stiffness by FibroScan, Enhanced Liver Fibrosis (ELF) scores, and serum biomarkers such as PRO-C3, YKL-40, and PRO-C4. Galectin Therapeutics often reports how these measures relate to the incidence of new esophageal varices and portal hypertension risk categories in patients with compensated MASH cirrhosis.
News items also cover regulatory interactions with the U.S. Food and Drug Administration, such as Type C meeting requests, written feedback on trial design, and plans for potential pivotal Phase 3 development of belapectin. Investors can find announcements about Fast Track designation, presentation of NAVIGATE data at major liver disease meetings like AASLD and EASL, and participation in investor conferences and virtual key opinion leader events.
In addition, Galectin Therapeutics issues press releases on quarterly financial results, new or extended lines of credit and convertible notes, and corporate governance matters. These updates provide context on the company’s capital resources, development priorities, and timing of planned activities. For anyone tracking GALT, this news feed offers a centralized view of clinical milestones, regulatory developments, financing arrangements, and strategic communications related to belapectin and the company’s broader galectin-targeted pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Galectin Therapeutics Inc. (NASDAQ: GALT) announced its participation in the H.C. Wainwright BioConnect Investment Conference on May 2, 2023. CEO Joel Lewis and CMO Dr. Pol F. Boudes will engage in a discussion about the NAVIGATE trial targeting NASH cirrhosis. A live webcast of the event will be available at 10:30 a.m. ET. Belapectin, the company's lead drug, targets galectin-3 and shows promise in reversing liver fibrosis. The NAVIGATE trial, evaluating belapectin's efficacy in preventing esophageal varices in NASH cirrhosis, has completed randomization with results expected in Q4 2024. NASH, affecting up to 28 million U.S. citizens, can lead to cirrhosis, where liver transplants are often the only treatment. The company aims to develop new therapies for chronic liver diseases and cancer.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
